SECsense Logo

Evaxion Biotech A/S Reports Major Change in ADS Structure - Form 6-K Filing

$EVAX
Form 6-K
Filed on: 2025-01-14
Source
Evaxion Biotech A/S Reports Major Change in ADS Structure - Form 6-K Filing

Here are the key insights extracted from the financial report (Form 6-K) for Evaxion Biotech A/S:

  1. Filing Details:
  • Type: Form 6-K
  • Filing Date: January 14, 2025
  • Commission File Number: 001-39950
  1. Company Information:
  • Name: Evaxion Biotech A/S
  • Address: Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark
  1. Regulatory Context:
  • The filing serves as a report for a foreign private issuer in accordance with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
  1. Key Announcement:
  • The company announced a change to its American Depositary Share (ADS) to ordinary share ratio:
    • Previous Ratio: 1 ADS = 10 ordinary shares
    • New Ratio: 1 ADS = 50 ordinary shares
  • This change became effective on January 14, 2025.
  1. Incorporation by Reference:
  • The report is incorporated by reference into various registration statements (Form S-8, Form F-3, and multiple Form F-1 filings).
  1. Signature:
  • The report is signed by Christian Kanstrup, Chief Executive Officer of Evaxion Biotech A/S, affirming the authenticity of the report.
  1. Exhibit:
  • A press release dated January 14, 2025, detailing the ADS ratio change is included as Exhibit 99.1.

This summary highlights the changes in the company's ADS structure, which could affect shareholder equity and investment perceptions, and confirms compliance with SEC regulations for foreign filers.